TAZVERIK
Peaktazemetostat hydrobromide
NDAORALTABLETPriority Review
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAZVERIK (tazemetostat hydrobromide) is an oral small-molecule EZH2 inhibitor approved in June 2020 for treating certain hematologic malignancies with EZH2 mutations or wild-type disease. The drug works by inhibiting epigenetic regulation through histone methyltransferase EZH2 suppression, enabling tumor cell differentiation and apoptosis.
Peak
TAZVERIK is in peak commercial phase with moderate competitive pressure (30), indicating active market demand and likely mid-to-large branded team operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TAZVERIK offers career opportunities in a peak-stage oncology product with specialized hematology focus. Positions on this brand typically involve navigating competitive markets and managing a complex indication portfolio.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.